We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Werfen Unveils Next Generation Hemostasis Testing Systems

By LabMedica International staff writers
Posted on 30 Jul 2025

Werfen (Barcelona, Spain) is unveiling the next generation of market-leading ACL TOP hemostasis testing systems at the ADLM Annual Meeting 2025, reinforcing the company’s commitment to innovation in specialized diagnostics. More...

Werfen also has announced the expansion of its award-winning Gem Premier 7000 with iQM3 to Europe, following its strong clinical adoption in North America.

Werfen had recently announced the commercialization of ACL TOP Family 70 Series hemostasis testing systems in North America, following 510(k) clearance by the US Food and Drug Administration and licensure by Health Canada. Building upon the company’s established legacy of quality and innovation in hemostasis testing, the ACL TOP Family 70 series hemostasis testing systems optimize workflow with a powerful combination of quality and efficiency, and connectivity across an entire laboratory network. To streamline and optimize workflow, ACL TOP Family 70 Series systems offer centralized QC and automated performance verification management. When connected to HemoHub Intelligent Data Manager, synergistic integration allows uniform application of a laboratory’s Quality Management System across multiple instruments and sites, from one centralized location; transcription errors are eliminated, and report generation and storage are automated. Performance verification studies that previously involved several manual processes are reduced to two automated steps, saving significant staff time, improving quality, and reducing costs.

At ADLM 2025, Werfen has announced the expanded commercialization for the GEM Premier 7000 with iQM3, following its early success in North America. Building on strong clinical adoption and recognition in the United States, the system is now available in Europe. The GEM Premier 7000 is the first blood gas testing system to integrate hemolysis detection at the point of care, addressing the most common preanalytical error in blood gas testing. The system earned five prestigious industry awards, including the 2025 Edison Award and Premier Inc. Supplier Innovation Award, for its groundbreaking integration of hemolysis detection at the point of care. These honors highlight its innovation, quality, and positive impact on clinical workflows and patient care.

Related Links:
Werfen


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.